<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496597</url>
  </required_header>
  <id_info>
    <org_study_id>VERGES 2017</org_study_id>
    <nct_id>NCT03496597</nct_id>
  </id_info>
  <brief_title>Early Stage Retinal Abnormalities in Type 1 Diabetes, Screened With OCT Angiography.</brief_title>
  <acronym>AwARD</acronym>
  <official_title>Early Stage Retinal Abnormalities in Type 1 Diabetes, Screened With OCT Angiography.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The improvement of imaging techniques in ophthalmology has made it possible to carry out a
      precise non-invasive study of the retinal microvascular network and to detect early
      abnormalities in retinal disorders. The presence of such early retinal abnormalities remains
      poorly known during type 1 diabetes and may be detected with OCT-angiography. Furthermore,
      the association with glycemic variability, likely to have deleterious effects on
      microvessels, has never been studied.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>surface of the central retinal avascular zone</measure>
    <time_frame>inclusion</time_frame>
    <description>measurement of superficial capillary plexus</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Type 1 Diabetes Patients</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>type 1 diabetes patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>non diabetic control subjects of the same age</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retinal imaging assessment</intervention_name>
    <description>OCT-angiography
Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus
Eye fundus photography: macular image
Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood glucose holter</intervention_name>
    <description>for 40 subjects, implantation of a blood glucose holter monitor for 7 days</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetes Type 1 patients followed in the Endocrinology Department of the CHU Dijon
        Bourgogne or in a diabetology surgery, and non-diabetic controls will be recruited in the
        Ophthalmology Department of the CHU Dijon Bourgogne
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For the patient group

          -  Patient who has given consent

               -  Type 1 diabetic patient, no retinopathy For the control group

          -  Patient who has given consent

          -  Non-diabetic patient

        Exclusion Criteria:

        For the patient group

          -  Presence of diabetic retinopathy

          -  Protected patient:

               -  Minor patient

               -  Pregnant, parturient or breastfeeding woman

               -  Patient under legal protection (guardianship, curatorship, court decision)

               -  Patient unable to express consent Person not affiliated to a health insurance
                  scheme

        For the control group

          -  Ophthalmological history (vascular and degenerative macular conditions)

          -  Protected patient:

               -  Minor patient

               -  Pregnant, parturient or breastfeeding woman

               -  Patient under legal protection (guardianship, curatorship, court decision)

               -  Patient unable to express consent Person not affiliated to a social security
                  scheme
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno VERGES, MD</last_name>
      <phone>03.80.29.38.54</phone>
      <email>bruno.verges@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

